Safety Alerts & Recalls

Search all Safety Alerts & Recalls

Latest Alerts

Angioedema and ACE inhibitors
This alert is to inform you about a reaction called angioedema which causes sudden swelling of the body, especially of the face (such as eyelids or lips), tongue, or throat, that may occur when you start or increase the dose of an ACE inhibitor (i.e., angiotensin-converting enzyme inhibitor) or a product that contains an ACE inhibitor, like ACCURETIC or QUINARETIC. African Americans and women seem to be at a higher risk for this reaction. Although information on this side effect is included in the current labeling for these medications, a new study reinforces that patients and their physicians should be aware of this side effect and what to do if it occurs. For more information, please visit: http://hyper.ahajournals.org/cgi/content/abstract/51/6/1624
Learn More

Recall - single lot of Watson brand 75 mcg/hr Fentanyl Transdermal System patches
Watson Pharmaceuticals, Inc has voluntarily recalled a single lot of 75 mcg/hr Fentanyl Transdermal System patches. The recalled patches, manufactured by Watson Laboratories, Inc, are from Lot Number 92461850, and have an expiration date of August 31, 2009. A small number of patches from this lot number were leaking fentanyl gel which may expose patients or caregivers directly to fentanyl gel. No other strengths or lots were affected and the company does not anticipate any product shortages as a result of this recall. For more information please visit: http://ir.watson.com/phoenix.zhtml?c=65778&p=irol-newsArticle&ID=1185651
Learn More

Date Published Title Drug Source
2008-08-12 Angioedema and ACE inhibitors Hydrochlorothiazide with Quinapril Hydrochloride MediGuard CRT
2008-08-11 Recall - single lot of Watson brand 75 mcg/hr Fentanyl Transdermal System patches Fentanyl Manufacturer
2008-08-11 Potential increased risk of birth defects Topiramate MediGuard CRT
2008-08-08 Combination use can lead to rare condition of muscle damage Simvastatin FDA
2008-08-08 Combination use can lead to rare condition of muscle damage Amiodarone FDA
2008-08-08 Combination use can lead to rare condition of muscle damage Lovastatin FDA
2008-08-08 Combination use can lead to rare condition of muscle damage Atorvastatin FDA
2008-08-08 Combination use can lead to rare condition of muscle damage Ezetimibe with Simvastatin FDA
2008-08-08 Combination use can lead to rare condition of muscle damage Atorvastatin and Amlodipine FDA
2008-08-08 Combination use can lead to rare condition of muscle damage Lovastatin and Niacin FDA
2008-08-05 Generic Manufacturer Recalls Several Drug Products Manufacturer
2008-08-05 Generic Manufacturer Recalls Several Drug Products Chlordiazepoxide with Clidinium Bromide Manufacturer
2008-08-05 Generic Manufacturer Recalls Several Drug Products Manufacturer
2008-08-05 Generic Manufacturer Recalls Several Drug Products Carisoprodol with Aspirin Manufacturer
2008-08-05 Generic Manufacturer Recalls Several Drug Products Soma Compound with Codeine Manufacturer
2008-08-05 Generic Manufacturer Recalls Several Drug Products Manufacturer
2008-08-05 Generic Manufacturer Recalls Several Drug Products Sodium Fluoride Manufacturer
2008-08-05 Generic Manufacturer Recalls Several Drug Products Multivitamin Manufacturer
2008-08-05 Generic Manufacturer Recalls Several Drug Products Vitaplex Manufacturer
2008-08-05 Generic Manufacturer Recalls Several Drug Products Vitaplex Comp Manufacturer
Back to Consumer Med Safety